0 53

Cited 0 times in

Prolactin ≤1 ng/mL predicts macroprolactinoma reduction after cabergoline therapy

Authors
 Daham Kim  ;  Cheol Ryong Ku  ;  Kyungwon Kim  ;  Hyein Jung  ;  Eun Jig Lee 
Citation
 EUROPEAN JOURNAL OF ENDOCRINOLOGY, Vol.182(2) : 177-183, 2020 
Journal Title
 EUROPEAN JOURNAL OF ENDOCRINOLOGY 
ISSN
 0804-4643 
Issue Date
2020
Abstract
Objective: The association between prolactin level variation and prolactinoma size reduction remains unclear. This study aimed to determine the prolactin level cut-off predictive of a tumor size reduction. Design: Retrospective cohort study. Methods: We reviewed medical records of patients with prolactinoma who received primary cabergoline therapy and for whom complete data on pituitary hormone assays and sellar MRI at baseline and 3 months post treatment were available. We tested whether the certain prolactin level after 3 months post treatment predicted better response. Results: Prolactin levels normalized in 109 (88.6%) of 123 included macroprolactinoma patients. The mean tumor size reduction was 22.9%, and patients in the lowest prolactin tertile (≤0.7) had the highest frequency of tumor size reductions of ≥20% (73.7 vs 52.9% and 45.9% in tertiles 2 (>0.7 to 2.6) and 3 (>2.6 to 20), P = 0.015). Patients with prolactin levels ≤1 ng/mL exhibited larger tumor size reductions vs those with prolactin levels of 1-20 (27.2 ± 18.3% vs 19.5 ± 13.9%, P = 0.014), 1-10 (19.3 ± 13.7%, P = 0.017) and 1-5 ng/mL (19.2 ± 14.3%, P = 0.039). A multivariable logistic regression analysis revealed that a prolactin level ≤1 ng/mL at 3 months and high-dose cabergoline therapy were significantly associated with tumor size reductions of ≥20% (odds ratio (OR): 2.8, 95% confidence interval (CI): 1.2-6.7, P = 0.017; OR: 2.0, 95% CI: 1.0-3.9, P = 0.043). Conclusions: A prolactin level ≤1 ng/mL at 3 months after cabergoline treatment was correlated with a significant tumor size reduction in patients with macroprolactinoma. This finding may help clinical decision making when treating macroprolactinoma patients.
Full Text
https://eje.bioscientifica.com/view/journals/eje/182/2/EJE-19-0753.xml
DOI
10.1530/EJE-19-0753
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Ku, Cheol Ryong(구철룡) ORCID logo https://orcid.org/0000-0001-8693-9630
Kim, Daham(김다함) ORCID logo https://orcid.org/0000-0003-1871-686X
Lee, Eun Jig(이은직) ORCID logo https://orcid.org/0000-0002-9876-8370
Jung, Hyein(정혜인)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/175281
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links